Rhonda Kuolee1, Wangxue Chen. 1. Institute for Biological Sciences, National Research Council Canada, Ottawa, Ontario K1A 0R6, Canada,
Abstract
BACKGROUND: M (microfold or membranous) cells are specialised epithelial cells responsible for antigen sampling at the interface of mucosal surfaces and the environment. Their high transcytotic ability make M cells an attractive target for mucosally delivered vaccines and therapeutics. OBJECTIVE: This brief review discusses the current state of M cell-targeted mucosal delivery systems and the potential of such delivery systems for the development of new vaccines and therapeutics against mucosal infectious and inflammatory diseases. SCOPE: A variety of synthetic microparticles/nanoparticles have been developed and tested as vehicles for M cell-targeted mucosal drug and vaccine delivery. beta1 integrins, pathogen recognition receptors, specific carbohydrate residues and other M cell surface antigens have been exploited as potential targets for the delivery of mucosal vaccines and therapeutics. CONCLUSION: Despite a considerable body of literature, much work still needs to be done before an effective M cell-targeted vaccine or therapeutic is developed.
BACKGROUND: M (microfold or membranous) cells are specialised epithelial cells responsible for antigen sampling at the interface of mucosal surfaces and the environment. Their high transcytotic ability make M cells an attractive target for mucosally delivered vaccines and therapeutics. OBJECTIVE: This brief review discusses the current state of M cell-targeted mucosal delivery systems and the potential of such delivery systems for the development of new vaccines and therapeutics against mucosal infectious and inflammatory diseases. SCOPE: A variety of synthetic microparticles/nanoparticles have been developed and tested as vehicles for M cell-targeted mucosal drug and vaccine delivery. beta1 integrins, pathogen recognition receptors, specific carbohydrate residues and other M cell surface antigens have been exploited as potential targets for the delivery of mucosal vaccines and therapeutics. CONCLUSION: Despite a considerable body of literature, much work still needs to be done before an effective M cell-targeted vaccine or therapeutic is developed.
Authors: Lissette S Velasquez; Samantha Shira; Alice N Berta; Jacquelyn Kilbourne; Babu M Medi; Ian Tizard; Yawei Ni; Charles J Arntzen; Melissa M Herbst-Kralovetz Journal: Vaccine Date: 2011-06-02 Impact factor: 3.641
Authors: Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam Journal: Clin Vaccine Immunol Date: 2009-02-11
Authors: Matthew G Panthani; Tarik A Khan; Dariya K Reid; Daniel J Hellebusch; Michael R Rasch; Jennifer A Maynard; Brian A Korgel Journal: Nano Lett Date: 2013-08-09 Impact factor: 11.189
Authors: Joshua J Reineke; Daniel Y Cho; Yu-Ting Dingle; A Peter Morello; Jules Jacob; Christopher G Thanos; Edith Mathiowitz Journal: Proc Natl Acad Sci U S A Date: 2013-08-06 Impact factor: 11.205
Authors: H Valpotić; A Kovšca Janjatović; G Lacković; F Božić; V Dobranić; D Svoboda; I Valpotić; M Popović Journal: Eur J Histochem Date: 2010 Impact factor: 3.188